Current Report Filing (8-k)
April 23 2020 - 4:12PM
Edgar (US Regulatory)
0000097745
false
0000097745
2020-04-16
2020-04-17
0000097745
us-gaap:CommonStockMember
2020-04-16
2020-04-17
0000097745
tmo:SeniorNotesFloatingRateDue2020Member
2020-04-16
2020-04-17
0000097745
tmo:SeniorNotes2.15Due2022Member
2020-04-16
2020-04-17
0000097745
tmo:SeniorNotes0.75Due2024Member
2020-04-16
2020-04-17
0000097745
tmo:SeniorNotes0.125Due2025Member
2020-04-16
2020-04-17
0000097745
tmo:SeniorNotes200Due2025Member
2020-04-16
2020-04-17
0000097745
tmo:SeniorNotes1.40Due2026Member
2020-04-16
2020-04-17
0000097745
tmo:A1.45SeniorNotesDue2027Member
2020-04-16
2020-04-17
0000097745
tmo:SeniorNotes175Due2027Member
2020-04-16
2020-04-17
0000097745
tmo:SeniorNotes0.500Due2028Member
2020-04-16
2020-04-17
0000097745
tmo:SeniorNotes1.375Due2028Member
2020-04-16
2020-04-17
0000097745
tmo:SeniorNotes1.95Due2029Member
2020-04-16
2020-04-17
0000097745
tmo:SeniorNotes0.875Due2031Member
2020-04-16
2020-04-17
0000097745
tmo:SeniorNotes2375Due2032Member
2020-04-16
2020-04-17
0000097745
tmo:SeniorNotes2.875Due2037Member
2020-04-16
2020-04-17
0000097745
tmo:SeniorNotes1.500Due2039Member
2020-04-16
2020-04-17
0000097745
tmo:SeniorNotes1.875Due2049Member
2020-04-16
2020-04-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current
Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): April 17, 2020
THERMO FISHER SCIENTIFIC INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
1-8002
|
|
04-2209186
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
168 Third Avenue
Waltham, Massachusetts
|
|
|
|
02451
|
(Address of Principal Executive Offices)
|
|
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code: (781) 622-1000
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, $1.00 par value
|
|
TMO
|
|
New York Stock Exchange
|
Floating Rate Notes due 2020
|
|
TMO /20A
|
|
New York Stock Exchange
|
2.150% Notes due 2022
|
|
TMO 22A
|
|
New York Stock Exchange
|
0.750% Notes due 2024
|
|
TMO 24A
|
|
New York Stock Exchange
|
0.125% Notes due 2025
|
|
TMO 25B
|
|
New York Stock Exchange
|
2.000% Notes due 2025
|
|
TMO 25
|
|
New York Stock Exchange
|
1.400% Notes due 2026
|
|
TMO 26A
|
|
New York Stock Exchange
|
1.450% Notes due 2027
|
|
TMO 27
|
|
New York Stock Exchange
|
1.750% Notes due 2027
|
|
TMO 27B
|
|
New York Stock Exchange
|
0.500% Notes due 2028
|
|
TMO 28A
|
|
New York Stock Exchange
|
1.375% Notes due 2028
|
|
TMO 28
|
|
New York Stock Exchange
|
1.950% Notes due 2029
|
|
TMO 29
|
|
New York Stock Exchange
|
0.875% Notes due 2031
|
|
TMO 31
|
|
New York Stock Exchange
|
2.375% Notes due 2032
|
|
TMO 32
|
|
New York Stock Exchange
|
2.875% Notes due 2037
|
|
TMO 37
|
|
New York Stock Exchange
|
1.500% Notes due 2039
|
|
TMO 39
|
|
New York Stock Exchange
|
1.875% Notes due 2049
|
|
TMO 49
|
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Common Stock, $1.00 par value
Item 1.01. Entry into a Material Definitive Agreement.
As previously
announced, on March 3, 2020, Thermo Fisher Scientific Inc. (“Thermo Fisher”) obtained committed debt financing
from JPMorgan Chase Bank, N.A. and Morgan Stanley Senior Funding, Inc. in connection with its entry into a
Business Combination Agreement with QIAGEN N.V.
On April 17,
2020, Thermo Fisher Scientific Inc. entered into a Bridge Credit Agreement,
as defined and further described below, which Bridge Credit Agreement is the definitive agreement related to the previously
obtained committed debt financing. Capitalized terms used in this Form 8-K and not defined herein shall have the meanings ascribed to
them in the Bridge Credit Agreement, which is attached to this Form 8-K as Exhibit 10.1 and incorporated herein by reference.
Bridge Credit Agreement
The Bridge Credit Agreement (“Bridge
Credit Agreement”) is a 364-day senior unsecured bridge loan facility in the principal amount of up to €9.25
billion (the “Bridge Commitments”), among Thermo Fisher, each lender from time to time party thereto, and JPMorgan
Chase Bank, N.A., as administrative agent (the “Administrative Agent”). Loans under the Bridge Credit Agreement (the
“Loans”) will be available in Euros to fund the purchase of equity securities of QIAGEN N.V. (“QIAGEN”)
pursuant to the Business Combination Agreement, dated as of March 3, 2020, between Thermo Fisher and QIAGEN (the “Combination
Agreement”) and to pay all or a portion of the cost incurred by Thermo Fisher or any of its subsidiaries in connection therewith.
The Loans will be available in up to two drawings as follows:
(i) the first drawing may be made on
the date (the “Closing Date”) (x) Thermo Fisher or one of its subsidiaries shall have accepted all outstanding equity
interests of QIAGEN validly tendered pursuant to a public tender offer (the
“Offer”) to purchase all issued ordinary shares, par value €0.01 per share, of QIAGEN at a price of €39
per QIAGEN share in cash, without interest, and shall have tendered payment for such equity interests in accordance with
the terms of the Combination Agreement or (y)(I) the Administrative Agent shall have received an officer’s certificate from
Thermo Fisher certifying that Thermo Fisher or one of its subsidiaries shall accept all outstanding equity interests that have
been validly tendered pursuant to the Offer and shall tender payment for such equity interests in accordance with the terms of
the Combination Agreement, in each case, within one business day following the Closing Date and (II) Thermo Fisher shall have caused
the proceeds of the Loans to be deposited with the settlement agent pursuant to the terms of the Offer documents or shall have
made such other arrangements reasonably satisfactory to the Administrative Agent for the payment of the equity interests that have
validly tendered pursuant to the Offer; and
(ii) the second drawing may be made at
any time on or prior to the date that is 120 days after the Closing Date.
If no Default or Event of Default has
occurred, (i) each Eurocurrency Rate Loan shall bear interest on the outstanding principal amount thereof for each Interest
Period at a rate per annum equal to the EURIBO Rate for such Interest Period plus a margin of 0.750% to 1.375% per annum
based on Thermo Fisher’s Debt Ratings and (ii) each Base Rate Loan shall bear interest on the outstanding principal
amount thereof from the applicable borrowing date at a rate per annum equal to the Base Rate plus a margin of 0.000% to
0.375% per annum based on Thermo Fisher’s Debt Ratings.
From June 1, 2020 and continuing through
and including the earlier of (i) the Closing Date or (ii) the date of termination of the Bridge Commitments, Thermo Fisher shall
pay a ticking fee equal to a rate between 0.070% and 0.175% per annum based on Thermo Fisher’s Debt Ratings times the actual
daily aggregate amount of the Bridge Commitments. The ticking fee is earned, due and payable on the earlier of the (i) Closing
Date and (ii) the date the Bridge Commitments are terminated. Thermo Fisher has also agreed to pay a funding fee equal to 0.50%
of the aggregate principal amounts of the Loans funded and a duration fee on each of the 90th, 180th and 270th day after the Closing
Date in an amount equal to 0.50%, 0.75% and 1.00%, respectively, of the aggregate amount of the Loans outstanding at the time.
The Bridge Credit Agreement contains
customary representations and warranties, as well as affirmative and negative covenants. The negative covenants include restrictions
on liens and fundamental changes. The Bridge Credit Agreement also requires that Thermo Fisher maintain (i) a consolidated indebtedness
to consolidated EBITDA ratio of no greater than 4.5 to 1.0 as of the last date of each of the first two full fiscal quarters ended
after the Closing Date, with such ratio stepping down to 4.0 to 1.0 for the last date of each of the two immediately following
fiscal quarters, and then stepping down to 3.5 to 1.0 of each fiscal quarter thereafter, subject to the right of Thermo Fisher
to increase such maximum consolidated leverage ratio tests in connection with certain qualified acquisitions and (ii) a consolidated
interest coverage ratio as of the last day of any fiscal quarter of Thermo Fisher (commencing with the first full fiscal quarter
completed at the Closing Date) of at least 3.0 to 1.0.
Item 2.03. Creation of a Direct Financial Obligation or an
Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The information set forth above under Item
1.01 is incorporated by reference into this Item 2.03.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
THERMO FISHER SCIENTIFIC INC.
|
|
|
|
|
|
|
Date: April 23, 2020
|
By:
|
/s/ Michael A. Boxer
|
|
|
Name:
|
Michael A. Boxer
|
|
|
Title:
|
Senior Vice President and General Counsel
|
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Sep 2023 to Sep 2024